A key focus of the campaign was evaluating the platform's active thermal management capabilities, including systems designed to support temperature control and thermal cycling during spaceflight - capabilities that are essential for life sciences research in microgravity. In addition, thermal sensors built into the payload were intended to monitor temperature changes in real time, providing scientists with valuable data about how the space environment affects the samples. Conditions found in space can accel ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: December 31, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to _________ Commission File Number 000-25434 AZENTA, INC. (Exact name of registrant as specified in its charter) Delaware 04 ...

Azenta logo 5 medical stocks growing earnings by triple digits Azenta (NASDAQ:AZTA) reported fiscal first-quarter 2026 revenue of $149 million, up 1% on a reported basis but down 1% organically, as continued macro uncertainty and cautious capital spending weighed on parts of its portfolio. Management reaffirmed full-year guidance calling for 3% to 5% organic revenue growth and roughly 300 basis points of adjusted EBITDA margin expansion, while acknowledging that the turnaround “will not be a straight ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2026 was $149 million, up 1% reported but down 1% organically, with a 2% headwind from foreign exchange [16][18] - Non-GAAP EPS for the first quarter was $0.09, and adjusted EBITDA margin was 8.5%, down approximately 230 basis points year-over-year [17][19] - Free cash flow for the quarter was $15 million, with cash, cash equivalents, and marketable securities totaling $571 million, an increase of $25 million quarter-over-quarter [17][18] Business Line Data and Key Metrics Changes - In Sample Management Solutions (SMS), revenue was $81 million, flat on a reported basis and down 2% organically, with growth in Biorepositories offset by declines in Automated Stores and Cryo [20][21] - Multiomics revenue was $67 million, up 1% reported and flat organically, with growth in Next-Generation Sequencing and Gene Synthesis, but continued weakness in Sanger Sequencing [21][22] Market Data and Key Metrics Changes - North America showed softness due to macro-driven budget constraints and a government shutdown, while Europe and Asia performed strongly, particularly with China showing 26% organic growth [22][74] - The overall market conditions remain mixed, with cautious capital spending decisions impacting bookings [9][10] Company Strategy and Development Direction - The company aims to embed operational excellence, accelerate growth, and expand margins as part of its turnaround strategy [8][10] - Focus on core portfolio and strategic capital deployment, including a $250 million share repurchase authorization [12][18] - The company is committed to a full-year 2026 guidance of 3%-5% organic revenue growth and adjusted EBITDA margin expansion of approximately 300 basis points [15][23] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about improvements in capital markets and M&A activity, expecting greater clarity around government and academic funding [9][10] - The company anticipates a transitional year for the life sciences sector, with expectations for acceleration in the second half of 2026 as delayed approvals are processed [10][15] Other Important Information - The sale of B Medical Systems is expected to close on or before March 31, 2026, further sharpening the company's focus on its core portfolio [12][16] - The company is addressing quality issues in Automated Stores, with remediation efforts expected to be completed by the end of Q2 [21][63] Q&A Session Summary Question: Can you talk about your level of confidence in getting the SMS margins back to where you want them to be? - Management acknowledged margin headwinds due to product and geographic mix but reiterated confidence in achieving guidance for the full year [25][28] Question: Can you characterize the conversations you've had with customers in the academic and government segments? - Management reported positive conversations and momentum in North America, with expectations for improvement in the back half of the year [32][33] Question: Can you talk about the level of comfort or visibility into key drivers for the second-half ramp? - Management expressed confidence in North America coming back, with growth investments in R&D and innovation expected to drive performance [36][37] Question: How are you thinking about performance in the U.S. academic market given flat NIH budgets? - Management noted a shift in funding towards larger projects and expressed optimism about supporting those programs [46][47] Question: What are you seeing from pharma and biotech customers right now? - Management indicated more clarity in the pharma and biotech markets, with ongoing investments and positive sentiment from customers [48][49] Question: Can you provide insight into the extra costs impacting gross margin? - Management detailed specific costs related to quality issues and lab inefficiencies, while emphasizing ongoing efforts to optimize margins [51][53]

Financial Data and Key Metrics Changes - Total revenue for Q1 2026 was $149 million, up 1% reported but down 1% organically, with a 2% headwind from foreign exchange [16][18] - Non-GAAP EPS for the first quarter was $0.09, and adjusted EBITDA margin was 8.5%, down approximately 230 basis points year-over-year [17][19] - Free cash flow, including B Medical, was $15 million for the quarter, with cash, cash equivalents, and marketable securities totaling $571 million, an increase of $25 million quarter-over-quarter [17][18] Business Line Data and Key Metrics Changes - In Sample Management Solutions, revenue was $81 million, flat on a reported basis and down 2% organically, with growth in biorepositories offset by softness in automated stores [20] - Multiomics revenue was $67 million, up 1% on a reported basis and flat organically, with growth in next-generation sequencing and gene synthesis, but continued weakness in Sanger sequencing [21][22] Market Data and Key Metrics Changes - North America experienced softness due to macro-driven budget constraints and a government shutdown, while Europe and Asia showed positive momentum [9][22] - China reported 26% organic growth in Multiomics, driven by strong demand in biotech and pharma [22][76] Company Strategy and Development Direction - The company aims to embed operational excellence, accelerate growth, and expand margins as part of its turnaround strategy [8][10] - Focus on core portfolio and strategic capital deployment, including a $250 million share repurchase authorization [12][18] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about improvement in capital markets and government funding, expecting greater clarity in the coming months [9][10] - 2026 is viewed as a transitional year for the life sciences sector, with expectations for acceleration in the second half of the year [10][23] Other Important Information - The sale of B Medical Systems is expected to close on or before March 31, 2026, further sharpening the company's focus on its core portfolio [12][16] - The company is committed to maintaining financial flexibility to support disciplined capital deployment [18] Q&A Session Questions and Answers Question: Can you talk about your level of confidence in getting the SMS margins back to where you want them to be? - Management acknowledged challenges due to product mix and quality issues but reiterated confidence in achieving margin targets through operational improvements [25][26] Question: Can you characterize the conversations you've had with customers in the academic and government segments? - Management reported positive conversations and momentum in North America, indicating a bullish outlook for the back half of the year [32][33] Question: What are your expectations for top-line performance in Q2 and the cadence from Q2 to Q3? - Management indicated an uplift in Q2 revenue but emphasized that significant growth is expected in the second half of the year [40][41] Question: How are you thinking about performance in the U.S. academic market given flat NIH budgets? - Management noted a shift in funding priorities and expressed confidence in supporting core labs and driving productivity [46][47] Question: What are you seeing from pharma and biotech customers right now? - Management observed more clarity and commitment from pharma and biotech customers, indicating a positive sentiment moving forward [48][49] Question: Where do you think you can find some of the offset to achieve the 300 basis point expansion? - Management highlighted several levers, including increased sales volume and operational efficiencies, to achieve margin expansion [51][53]

Financial Data and Key Metrics Changes - Total revenue for Q1 2026 was $149 million, up 1% reported but down 1% organically, with a 2% headwind from foreign exchange [14][16] - Non-GAAP EPS for the first quarter was $0.09, and adjusted EBITDA margin was 8.5%, down approximately 230 basis points year-over-year [15][17] - Free cash flow for the quarter was $15 million, with cash, cash equivalents, and marketable securities totaling $571 million, an increase of $25 million quarter-over-quarter [15][16] Business Line Data and Key Metrics Changes - In Sample Management Solutions, revenue was $81 million, flat on a reported basis and down 2% organically, with growth in biorepositories offset by declines in automated stores and cryo [18][19] - Multiomics revenue was $67 million, up 1% on a reported basis and flat organically, with growth in next-generation sequencing and gene synthesis, but weakness in Sanger sequencing [19][20] - Gross margin for Sample Management Solutions was 45.4%, down 370 basis points year-over-year, primarily due to higher rework costs on automated stores projects [19] Market Data and Key Metrics Changes - Positive momentum was observed in Europe, while North America remained slow, impacted by macroeconomic conditions and a government shutdown [6][8] - China showed strong performance with 26% organic growth in Multiomics, driven by demand in biotech and pharma [20][77] - The overall market conditions are mixed, with cautious capital spending decisions across parts of the life sciences ecosystem [6][8] Company Strategy and Development Direction - The company aims to embed operational excellence, accelerate growth, and expand margins as part of its strategic priorities for 2026 [6][11] - A definitive agreement for the sale of B Medical was announced, expected to close by March 31, 2026, which will sharpen focus on core portfolio and enhance financial flexibility [11][14] - The company is committed to disciplined capital deployment and has a $250 million share repurchase authorization to return value to shareholders [11][16] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about improvements in capital markets and renewed M&A activity, expecting greater clarity around government and academic funding [6][8] - The company anticipates acceleration in the second half of 2026 as delayed approvals are processed and capital investment ramps up [9][13] - Management remains confident in achieving full-year guidance of 3%-5% organic revenue growth and adjusted EBITDA margin expansion of approximately 300 basis points [13][22] Other Important Information - The company continues to focus on operational improvements through the Azenta Business System, which drives measurable improvements in delivery, quality, and productivity [10] - The company is addressing quality issues in automated stores, with remediation efforts expected to be completed by the end of Q2 [19][64] Q&A Session Summary Question: Can you discuss your confidence in getting SMS margins back to desired levels? - Management acknowledged product mix and geo mix causing margin headwinds but expressed confidence in addressing these issues and reiterated guidance for the full year [24][25] Question: What are your expectations for top-line performance in Q2? - Management indicated that while they do not guide quarterly, they expect an uplift in revenue compared to Q1, with significant growth anticipated in the second half of the year [41][42] Question: How are you addressing the quality issues in automated stores? - Management detailed efforts to resolve quality issues and emphasized structural alignment to better serve customers, indicating that they are on track to meet customer needs [64][66] Question: What is the outlook for growth in the pharma and biotech sectors? - Management noted increased clarity and confidence in the pharma and biotech sectors, with ongoing investments and positive conversations with customers [49][50]

© 2026 Azenta, Inc. • All rights reserved Safe Harbor Statement Safe Harbor Statement This presentation contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding future financial performance including our fiscal year 2026 guidance, business trends, market demand, operational initiatives, strategic priorities, and other expectations or forecasts. These statements are based ...

Exhibit 99.1 Azenta Reports First Quarter Results for Fiscal 2026, Ended December 31, 2025 | | | | | | Quarter Ended | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | December | | September | | December | | | | | Dollars in millions, except per share data | 31, | | 30, | | 31, | | Change | | | | 2025 | | 2025 | | 2024 (1) | | Prior Qtr | Prior Yr. | | Revenue from Continuing Operations | $ | 149 | $ | 159 | $ | 147 | (7)% | 1% | | Organic growth | | | | | | | | (1)% | | Sample Management S ...

BURLINGTON, Mass., Feb. 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale and the entry into a definitive agreement to sell the business, which is expected to close on or before March 31, 2026. Quarter Ended | Dolla ...

Financial Data and Key Metrics Changes - The company ended the fiscal year with a strong cash balance of $546 million, providing financial flexibility for strategic investments and shareholder returns [3] - Fiscal 2025 was described as a turnaround year, with growth in core businesses and meaningful margin expansion despite a challenging macro environment [2] Business Line Data and Key Metrics Changes - Specific data on individual business lines was not provided in the meeting, but the overall performance indicated growth in core businesses [2] Market Data and Key Metrics Changes - No specific market data or key metrics changes were discussed during the meeting [2][3] Company Strategy and Development Direction - The company outlined a multi-year strategic roadmap during an Investor Day, which includes a $250 million share repurchase program [3] - A definitive agreement to divest B Medical was announced, with the transaction expected to close by March 31, 2026, indicating a focus on streamlining operations [3] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's leadership and operational momentum, positioning Azenta for durable growth and long-term profitable value creation for shareholders [3] Other Important Information - The meeting included the election of directors, a non-binding advisory vote on executive compensation, and the ratification of independent auditors for fiscal year 2026 [7][10] Q&A Session Summary - No specific questions or answers were recorded in the provided content, as the meeting primarily focused on formal business and strategic updates [2][3]